- See more
See all on WikipediaCediranib - Wikipedia
Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration. See more
Beginning in 2007, it underwent phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in … See more
Findings from a federally funded, NCI-sponsored phase II clinical trial presented at the 50th Annual Meeting of the American Society of … See more
Wikipedia text under CC-BY-SA license Cediranib: Uses, Interactions, Mechanism of Action - DrugBank …
Cediranib is a small molecule drug that blocks the activity of VEGF receptors, which are involved in tumor growth and angiogenesis. It is being developed for var…
- Generic Name
1. Cediranib - DrugBank Accession Number
1. DB04849
- Generic Name
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor ...
Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit. We conducted a phase II study of cediranib for …
Cediranib | C25H27FN4O3 | CID 9933475 - PubChem
The novel indole -ether quinazoline Cediranib is a highly potent (IC 50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
- bing.com › videosWatch full video
Cediranib – Profile of a novel anti-angiogenic agent in patients …
We summarize both pre-clinical and clinical data for cediranib with a focus on the treatment of glioblastomas. Cediranib is an effective drug in patients with glioblastoma acting through …
Randomized Trial of Olaparib With or Without …
Oct 18, 2022 · Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, suppresses expression of homologous recombination repair (HRR) genes and increases sensitivity to poly- (ADP-ribose) polymerase inhibition in …
- People also ask
Update on Phase III GY004 trial for cediranib added to Lynparza in ...
Mar 12, 2020 · Cediranib is an oral vascular endothelial growth factor (VEGF) receptor inhibitor that has demonstrated efficacy as a monotherapy and in combination in various cancers. …
Cediranib, a pan-inhibitor of vascular endothelial growth factor ...
Dec 15, 2021 · Key findings: Cediranib reduced GB cell proliferation, induced apoptotic cell death and inhibited the aggressive abilities of GB cells. Cediranib synergistically increased the anti …
Cediranib: Uses, Dosage, Side Effects, Food Interaction & FAQ
Jan 7, 2025 · Cediranib is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors. The preclinical profile of Cediranib …
Cediranib, a pan-inhibitor of vascular endothelial growth factor ...
Dec 15, 2021 · Cediranib (Astrazeneca) is a pan-inhibitor of the VEGF receptors and as well as PDGF-b and c-Kit. By inhibiting ligand-induced receptor tyrosine kinase activity of VEGFRs …
Skip to content
